Supplements for high-altitude travelers

Acetazolamide remains the gold standard for AMS prevention; the supplement layer is narrow and mostly about iron status and acclimatisation foundations.

High-altitude illness (acute mountain sickness, HACE, HAPE) is driven by the physiologic response to hypoxia and accelerated by rapid ascent. The Wilderness Medical Society guidelines are clear: graded ascent (sleeping altitude gains ≤500 m/day above 2500 m, with rest days), adequate hydration, and acetazolamide prophylaxis for high-risk profiles. Supplements play a small adjunctive role — iron status is genuinely important because hypoxic adaptation requires red-cell production, and a handful of botanicals have small trial signals. The list is short on purpose. Nothing on this page substitutes for acclimatisation.
82
Iron repletion (if ferritin low)
Hypoxic adaptation needs iron · Test ferritin pre-trip
Tier 1
83
Vitamin D3
Foundational; immune and muscle
Tier 1
90
Electrolyte complex (Na/K/Mg)
Diuresis at altitude · Hydration
Tier 1
78
Melatonin (low-dose 0.3–1 mg)
Sleep disruption at altitude common
Tier 2
66
Rhodiola rosea
Small AMS-prevention trials, mixed results
Tier 3
55
Coca-leaf tea (traditional Andean use)
Cultural use; not exportable; regulatory limits
Tier 3
48
Ginkgo biloba
Older positive trials; modern replication failed
Tier 3

The altitude-traveler stack — rationale by ingredient

Iron repletion (if ferritin is low) — start 6–8 weeks before departure

Hypoxic adaptation involves increased erythropoietin and red-cell production; iron-deficient travelers acclimatise worse and report more AMS symptoms. Check ferritin 6–8 weeks before a high-altitude trip; aim for a ferritin >30 ng/mL (some experts suggest >50 ng/mL for serious altitude objectives). Use ferrous bisglycinate (gentle iron) 25–50 mg elemental every other day for better absorption and tolerability than daily dosing.

Vitamin D3 to a 25-OH-D of 30–50 ng/mL

Foundational immune and muscle support. Particularly relevant in winter mountain travel from low-sun-exposure baselines.

Electrolyte complex (Na/K/Mg) at altitude

Altitude diuresis is real — increased urine output is part of the acclimatisation response and dehydration accelerates AMS. Pair fluid intake with electrolyte replacement, especially during exertion. Sodium-containing oral rehydration is better than plain water for active days.

Low-dose melatonin 0.3–1 mg before bed

Sleep is reliably disrupted at altitude. Low-dose melatonin (not the 5–10 mg consumer doses) is the best-evidenced sleep adjunct. Avoid the high-dose products — they sediment but don't improve circadian alignment and can produce next-day grogginess on summit days.

Rhodiola rosea — try if you're curious, but don't rely on it

The small AMS-prevention trial base is mixed. Reasonable to add at the standard 200–400 mg/day SHR-5 extract starting 1 week before ascent. Do not substitute for acetazolamide in high-risk profiles.

What to skip

Educational reference, not medical advice. Acute mountain sickness can progress to high-altitude cerebral or pulmonary oedema, both life-threatening. Plan with a travel-medicine clinician, especially for trips above 3500 m or with limited rest days. Acetazolamide remains the prophylaxis of choice in high-risk profiles. Descend at the first sign of severe headache, ataxia, confusion, or dyspnoea at rest.

Sources

  1. Luks AM, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2024 update. Wilderness Environ Med. 2024;35(1S):2S–19S.
  2. Gertsch JH, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004;328(7443):797. PMID: 15070635
  3. Govus AD, et al. Iron status in elite young athletes: interaction of energy availability and altitude exposure. Eur J Appl Physiol. 2014;114(4):745–755. PMID: 24390603
  4. Lippl FJ, et al. Hypobaric hypoxia causes body weight reduction in obese subjects. Obesity. 2010;18(4):675–681. PMID: 19696757
  5. Schoonman GG, et al. The headache during high altitude exposure: pathophysiology and clinical relevance. Cephalalgia. 2008;28(7):710–717.
  6. Ryan BJ, et al. Iron and altitude: effects of altitude exposure on iron metabolism. Eur J Appl Physiol. 2018;118(4):705–720. PMID: 29399742